In agreement with the results of the above-mentioned studies, our results demonstrated that pancreatic kallikrein treatment could reduce the production of ROS, downregulating NOX2 and upregulating the antioxidant SOD2 in both type 2 diabetic mouse models. This evidence concerns the gene KLK4 and type 2 diabetes mellitus.